Clinical Trial Detail

NCT ID NCT02846623
Title Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Atezolizumab + Obinutuzumab + Venetoclax

Age Groups: adult senior

No variant requirements are available.